Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1500648800HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Pay-for-delay: Is cash the only antitrust test that matters in patent settlements?

20.03.2014 / Fierce Pharma

Patent settlements between drugmakers and generic manufacturers have drawn even more scrutiny since the U.S. Supreme Court ruled last summer that the Federal Trade Commission has a right to challenge them. At issue are "pay-for-delay" deals, in which manufacturers of branded drugs pay generics challengers to refrain from launching copies until an agreed-upon date.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: